Eyconis, Inc.

REDWOOD CITY, CA · Founded 2023 · Biotech · Private

Novel small molecule and biologic therapies for eye diseases

Claim this profile

Follows are private to you and power your alerts

Updated · eyconis.com

Sector
Biotech
Headquarters
REDWOOD CITY, CA
Founded
2023
Latest Form D
$25M, Oct 2025
Total capital
$85.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$85.3M
2 Form D · last Oct 2025
12 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20242025FEDERAL ↑EQUITY ↓Cumulative $85.3M1st Form D$60.3M2nd Form D$25M
20242025FEDERAL ↑EQUITY ↓Cumulative $85.3M1st Form D$60.3M2nd Form D$25M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$25M
  • Private capital raisedForm D · SEC · 1st filing$60.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Anna ChenExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Conrad Moller WangDirectorNamed in SEC Form D filings
  • Dan EstesDirectorNamed in SEC Form D filings
  • Daniel EstesExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Emmett CunninghamExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Gordon Moller EmpeyExecutive Officer, PromoterNamed in SEC Form D filings
Show all 11 people
  • Jan Moller MikkelsenDirectorNamed in SEC Form D filings
  • Mark BachledaExecutive Officer, DirectorNamed in SEC Form D filings
  • Oliver Moller StauchExecutive OfficerNamed in SEC Form D filings
  • Robert Moller VittiExecutive OfficerNamed in SEC Form D filings
  • Yvonne Moller YamanakaDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • iECURESimilar federal contract value in Biotech · null in contracts
  • Pathos AI, Inc.Similar federal contract value in Biotech · null in contracts
  • Volastra TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Eikon TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Perspective Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Accent TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .